Long-term clinical efficacy and a possible mechanism of action of different modes of pneumococcal vaccination in asthma patients

Протасов, А. Д.; Жестков, А. В.; Костинов, М. П.; Корымасов, Е. А.; Штейнер, М Л; Тезиков, Ю В; Липатов, И. С.; Решетникова, В. П.; Lavrenteva, N E

doi:10.18093/0869-0189-2018-28-2-193-199

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant increase in economic losses due to direct and indirect costs up to 61.6 billion rubles is a negative contribution due to progressive COPD [14]. PI contributes to the sensitization and exacerbation of chronic non-specific inflammation in the bronchi, increases their hyperreactivity in the patients with bronchial asthma [15,16]. In the presence of kidney diseases, PI is more common than generally in the population, and it is more severe, with possible fatal outcomes.…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Орлова

Дорфман

Орлов

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

The aim. To evaluate the economic efficiency and the choice of the vaccination strategy in the respiratory pneumococcal infection risk groups among the adult population of the Astrakhan region.Materials and methods. The data for the period of 2015 - 2018 were analyzed on the number of registered diseases in the patients living in the service area of the medical organizations (Form No. 12, Federal State Statistics Service Orders No. 591, dated 27 November, 2015; No. 679, dated 22 November, 2019). The following working directives were studied: the base medical examination documentation submitted by medical institutions (Form No. 030/y “Dispensary Monitoring Checklist”; lists of the persons subjected to medical observation in the reporting year; Orders of the Ministry of Health of the Russian Federation: No. 1344, dated 12 December, 2012; No. 173n, dated 29 March, 2019). Statistical materials of the territorial fund for compulsory medical insurance of the Astrakhan region on the payment of medical care to 12,970 patients who had had pneumonia in 2015-2018, were analyzed. The financial support of vaccination based on the results of tenders for the procurement of pneumococcal vaccines organized by the regional Ministry of Health, was considered. The calculations were carried out in accordance with the guidelines of “Cost-effectiveness of vaccine prophylaxis” (Methodological guidelines 3.3.1878-04, dated 04.03.2004).Results. The prospective calculation of the vaccination cost showed that the benefits of vaccination with pneumococcal conjugate vaccine Prevenar13 (PCV13) and pneumococcal polyvalent vaccine Pneumovax 23 (PPV23) with a 95% vaccination coverage, are recorded after 2 years. The economic benefit of vaccination by reducing the possible number of pneumonias at the end of 2028 will be 968.2 million rubles.Conclusion. The economic feasibility of vaccine prophylaxis of the adult contingent with an increased risk of developing pneumococcal infection has been established. The sequential strategy of PCV13 and PPV23 application provides the most effective localization of pneumococcal infection. The research results should be widely introduced into the long-term plans for vaccination and healthcare practice in the Astrakhan region.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Орлова

Дорфман

Орлов

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

show abstract

Analytical review of respiratory infections role in patients with chronic obstructive pulmonary disease and asthma. Part 2. Prevention of occurrence and severe course of respiratory infections

Smirnova,

Antipushina,

Kontsevaya

et al. 2024

Profil. med.

View full text Add to dashboard Cite

Prospects of vaccination against pneumococcal infection based on the asthma phenotype

Kostinov,

Konishcheva

2024

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

According to recent studies, bronchial asthma is characterized by a wide variability of the mechanisms of occurrence and progression. This heterogeneity is caused by patterns of predominant cells and inflammatory mediators, which determine differences in immunological parameters observed in patients with certain endotypes depending on the dominant type of mediators (high and low T2 inflammation). In long-term observations, a substantial research base has been accumulated justifying the effectiveness of vaccination against pneumococcal infection in patients with asthma. The vaccination decreases the frequency of exacerbations of the disease and hospitalizations in the short and medium term. However, these studies evaluated the asthma patients as a wholesome population, and it remains unexplored whether the effect of pneumococcal vaccines on asthma differs depending on the endotype of the disease and what are the mechanisms of such a differentiated effect.The aim of this work is to present the results of recent quality studies on changes in the profile of inflammatory asthma mediators under the action of immunobiological substances based on Streptococcus pneumoniae antigens, primarily from the vaccines.Conclusion. The asthma heterogeneity can lead to different clinical outcomes in pneumococcal infection and, respectively, the clinical effects of immunization in patients differentiate according to the nature of inflammation. In other words, the uniformity of the clinical effect of vaccination against pneumococcal infection in all patients in ongoing studies may represent the combined effect of molecular mechanisms regulating the specific activity of Th1-, Th2-, Th17-, NKT-, and Treg-cells. The results of studies proving the ability of pneumococcal vaccines to modulate the Th1-, Th2-, Th17-, Treg immune response in patients with asthma contributed to increased interest in developing new immunoregulatory therapeutic agents based on S. pneumoniae antigens.

show abstract

Long-term clinical efficacy and a possible mechanism of action of different modes of pneumococcal vaccination in asthma patients

Cited by 7 publications

References 0 publications

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Analytical review of respiratory infections role in patients with chronic obstructive pulmonary disease and asthma. Part 2. Prevention of occurrence and severe course of respiratory infections

Prospects of vaccination against pneumococcal infection based on the asthma phenotype

Contact Info

Product

Resources

About